Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Ryman Healthcare (RYM.NZ)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (NZ$)	Price Target (NZ$)	Rating
2022-02-28	10.00	11.90	Sell
2022-03-02	9.55	10.50	Neutral
2022-05-21	9.85	10.90	Neutral
2022-07-04	8.96	9.95	Neutral
2022-10-10	8.45	9.60	Neutral
2022-11-21	7.44	8.55	Neutral
2023-02-07	6.30	7.05	Neutral
2023-02-15	6.40	-	No Rating
2023-04-25	5.35	6.75	Buy
2023-05-19	6.06	7.10	Buy
2023-06-27	6.48	7.50	Buy
2023-10-26	5.43	8.55	Buy
2023-11-29	5.22	8.10	Buy
2024-02-19	4.88	7.30	Buy
2024-05-27	3.82	6.20	Buy
2024-06-25	3.70	6.00	Buy
2024-09-02	4.90	6.30	Buy
2024-11-28	4.70	5.70	Buy
2025-02-11	4.37	6.00	Buy
2025-02-25	3.08	5.20	Buy
2025-03-04	3.03	4.70	Buy
2025-05-30	2.10	3.50	Buy

Disclosures

UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.